Lannett Company, Inc. (LCI) Given Consensus Rating of “Hold” by Brokerages
Shares of Lannett Company, Inc. (NYSE:LCI) have been assigned an average rating of “Hold” from the eight analysts that are covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and two have assigned a buy rating to the company. The average 1-year price target among brokers that have covered the stock in the last year is $21.50.
A number of research firms have weighed in on LCI. Zacks Investment Research cut Lannett from a “buy” rating to a “hold” rating in a report on Wednesday, December 13th. Oppenheimer restated a “hold” rating on shares of Lannett in a report on Monday, December 11th. ValuEngine upgraded Lannett from a “hold” rating to a “buy” rating in a report on Saturday, November 25th. Finally, BMO Capital Markets increased their target price on Lannett from $20.00 to $22.00 and gave the company a “market perform” rating in a research note on Monday, November 13th.
In other news, major shareholder David Farber sold 9,816 shares of the stock in a transaction that occurred on Tuesday, December 5th. The stock was sold at an average price of $30.05, for a total transaction of $294,970.80. Following the completion of the transaction, the insider now directly owns 4,190,169 shares in the company, valued at approximately $125,914,578.45. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, CEO Arthur P. Bedrosian sold 7,422 shares of the stock in a transaction that occurred on Wednesday, November 8th. The shares were sold at an average price of $25.20, for a total value of $187,034.40. Following the transaction, the chief executive officer now owns 679,001 shares of the company’s stock, valued at $17,110,825.20. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 140,000 shares of company stock valued at $3,681,091. Company insiders own 14.72% of the company’s stock.
Lannett (NYSE LCI) traded down $0.10 during midday trading on Monday, reaching $24.75. The company’s stock had a trading volume of 452,000 shares, compared to its average volume of 630,767. The stock has a market cap of $933.07, a PE ratio of 22.10, a PEG ratio of 1.63 and a beta of 2.85. Lannett has a 52-week low of $14.90 and a 52-week high of $30.35. The company has a debt-to-equity ratio of 1.44, a quick ratio of 1.90 and a current ratio of 2.52.
Lannett (NYSE:LCI) last released its quarterly earnings results on Monday, November 6th. The company reported $0.60 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.52 by $0.08. The firm had revenue of $155.00 million during the quarter, compared to analysts’ expectations of $153.62 million. Lannett had a return on equity of 18.23% and a net margin of 6.67%. Lannett’s quarterly revenue was down 4.1% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.77 EPS. equities analysts anticipate that Lannett will post 3.04 EPS for the current fiscal year.
ILLEGAL ACTIVITY WARNING: “Lannett Company, Inc. (LCI) Given Consensus Rating of “Hold” by Brokerages” was first posted by American Banking News and is the property of of American Banking News. If you are reading this story on another domain, it was illegally stolen and reposted in violation of United States and international copyright legislation. The correct version of this story can be accessed at https://www.americanbankingnews.com/2018/01/15/lannett-company-inc-lci-given-consensus-rating-of-hold-by-brokerages.html.
Lannett Company, Inc develops, manufactures, markets and distributes generic versions of brand pharmaceutical products. The Company manufactures and/or distributes prescription products with the exception of a small portfolio of over-the-counter products manufactured by its subsidiary, Silarx Pharmaceuticals, Inc As of June 30, 2016, the Company’s products included Acetazolamide Tablets; Butalbital, Acetaminophen and Caffeine Tablets; Butalbital, Aspirin and Caffeine Capsules; C-Topical Solution; Digoxin Tablets; Glycolax Rx; Isosorbide Mononitrate CR; Levothyroxine Sodium Tablets; Methylphenidate HCL CD; Methylphenidate ER; Nifedipine CR; Omeprazole DR; Oxbutynin ER; Pantoprazole DR; Pilocarpine HCl Tablets; Triamterene w/Hydrochlorothiazide Capsules, and Ursodiol Capsules.
Receive News & Ratings for Lannett Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lannett and related companies with MarketBeat.com's FREE daily email newsletter.